InvestSMART

TrivarX Ltd (ASX:TRI)

ALERT: Price-sensitive ASX Announcement for TRI
Current share price for TRI : $0.023 -0.005 (-17.86%)+
Announcement
Release
5 Nov 2025 8:48AM
Price at Release
$0.028
Full Release
download
Summary
TrivarX Limited has announced that it has exercised its option to acquire the Stabl-Im technology, a non-invasive method for imaging brain cancers through stable isotope labelling. This technology offers the potential to detect proliferating tumour cells early, addressing a significant need in the diagnostics of brain metastases. The acquisition is pending shareholder approval, expected to be discussed in a meeting in December 2025. Post-approval, TrivarX plans to conduct manufacturing and quality-control validation, engage with regulatory authorities, and start a Phase 1 clinical trial in 2026.
Key Points
  • TrivarX Limited exercises its option to acquire Stabl-Im technology.
  • Stabl-Im enables non-invasive imaging of brain cancers using stable isotope labelling.
  • Shareholder approval required for acquisition, meeting expected in December 2025.
  • Potential to advance early detection and monitoring of brain metastases.
  • TrivarX plans to initiate manufacturing, regulatory engagements, and a Phase 1 clinical trial in 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.